A new study has uncovered a correlation between psychological distress and genital and urinary health problems in female survivors of childhood sexual abuse.
The kidneys often become bulky and dysfunctional in diabetes, and now scientists have found that one path to this damage dramatically reduces the kidney's ability to clean up after itself.
Awareness of erectile dysfunction (ED) is alarmingly low in men and women aged 20 to 70, a new survey commissioned by the European Association of Urology (EAU) has revealed. A majority of the respondents do not know what ED exactly entails, and one in four has never heard of any of the seven most common treatments for ED.
Researchers at the University of Cambridge and the University of Zurich have discovered that a drug newly approved for cancer improves kidney dysfunction in a mouse model of Dent disease 2 and Lowe syndrome
Prophylactic treatment with direct-acting antivirals (DAAs) prevented chronic hepatitis C virus (HCV) infection in 10 patients receiving kidneys from HCV positive deceased donors. This approach has potential to help shorten waiting times on the organ waitlist. A brief research report is published in Annals of Internal Medicine.
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy. Future studies should determine the effectiveness of integration in cancer survival analysis and the application on unbalanced data, where the classes are of different sizes, as well as on data with multiple classes.
The North American Menopause Society (NAMS) announces publication of its 2020 Genitourinary Syndrome of Menopause (GSM) Position Statement. The new recommendations reflect the healthcare community's most recent and proven safe and effective therapies for treating women with GSM, including intravaginal dehydroepiandrosterone (DHEA), oral ospemifene, and a low-dose estradiol vaginal insert. The position statement is available online and will be published in the September issue of Menopause, the journal of NAMS.
The CREDENCE trial  provided evidence that the SGLT2 inhibitor Canagliflozin slows the progression of CKD in individuals with type 2 diabetes (T2D) and CKD with albuminuria. The Phase III DAPA-CKD trial  has now shown that the SGLT2 inhibitor Dapagliflozin can significantly slow CKD progression in all CKD patients, not only in those with diabetes. This breakthrough in kidney disease treatment goes back to an incidental study finding of Professor Christoph Wanner, President of the ERA-EDTA.
A new study shows that nephrologists do not always agree on their interpretation of images from urine sediment tests, which are frequently ordered to evaluate a variety of kidney diseases. Led by researchers at Boston Medical Center and published in JAMA Network Open, the findings indicate the need to standardize education and training around evaluating urine sediment tests to improve the test's reliability, and help prevent misinterpretation and potential patient harm.
A joint research project has successfully reproduced the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD) from human iPS cells in vitro. Although cysts derived from renal tubules have been previously documented, this is the first derivation of cysts from collecting ducts, which is more closely related to the pathogenesis of the disease. This research is expected to lead to a better understanding of disease states and the development of new treatment methods.